Nirav Shah, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Lilly Oncology
    Topic:
    Consulting/Advisory Board/Research Funding/Travel/Honoraria
    Date added:
    03/19/2023
    Date updated:
    05/07/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Miltenyi Biotec
    Topic:
    Consulting/Advisory Board/Research Funding/Travel/Honoraria
    Date added:
    03/19/2023
    Date updated:
    05/07/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Gilead-Kite
    Topic:
    Consultant/Advisory Board
    Date added:
    03/19/2023
    Date updated:
    05/07/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Incyte
    Topic:
    Consultant/Advisory Board
    Date added:
    03/19/2023
    Date updated:
    05/07/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Janssen
    Topic:
    Consultant/Advisory Board
    Date added:
    03/19/2023
    Date updated:
    05/07/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    BMS-Juno
    Topic:
    Consultant/Advisory Board
    Date added:
    03/19/2023
    Date updated:
    05/07/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Seattle Genetics
    Topic:
    Consultant/Advisory Board
    Date added:
    03/19/2023
    Date updated:
    05/07/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    TG Therapeutics
    Topic:
    Consultant/Advisory Board
    Date added:
    03/19/2023
    Date updated:
    05/07/2024
  • Type of financial relationship:
    Independent contractor
    Ineligible company:
    Epizyme
    Topic:
    Consultant/Advisory Board
    Date added:
    03/19/2023
    Date updated:
    05/07/2024
  • Type of financial relationship:
    Independent contractor
    Ineligible company:
    Genentech
    Topic:
    Research funding/travel/honoraria
    Date added:
    05/07/2024
    Date updated:
    05/07/2024

Pages

Return to 2024 Summit on Hematological Cancers